What nutritional advice should be given while on anticoagulant medication?

Tara Lech, PharmD is an Anticoagulation and Cardiovascular Clinical Pharmacy Specialist and currently serves as the Thrombosis Program Manager at Lahey Hospital and Medical Center in Burlington, MA. She recently joined NATF for an interactive Ask the Expert panel and answered several questions about anticoagulation, vitamins, supplements, herbs, and food. If you take a blood thinner, here’s what you should know.

Q: What can you tell us about interactions between anticoagulants and vitamins or nutritional supplements?

It’s challenging to navigate the world of supplements, and that’s why it’s so important to make your anticoagulation provider aware of any supplements that you’re taking. Even though supplements are available over the counter (OTC), it doesn’t mean that they’re risk-free. Some very common supplements and herbs can have a significant anticoagulation effect and may impact your body’s ability to either clot or bleed. Another thing to keep in mind is that supplements are not regulated, so there may be differences in manufacturing that could affect risk as well.

Q: Which herbs or supplements most commonly interact with anticoagulation?

Some of the big ones that we see in my clinic are herbs, like turmeric, ginger, or garlic, and oils, like grapeseed oil, as well as some OTC supplements, such as ginkgo biloba and vitamin E. There are several things to consider before using these herbs or supplements.

Q: Since many herbs and spices are commonly found in foods or used in cooking, what should people be aware of if they’re on anticoagulation?

Food interactions are more of a concern with warfarin than with direct oral anticoagulants (DOACs), and I always tell my patients to remember that taking warfarin isn’t a “life sentence.” While there can be some interaction between warfarin and the vitamin K in food, you can still eat what you want in moderation. It’s important to know that you don’t have to eat the same exact things every day, you don’t have to count how much vitamin K is in every food you eat, and you can enjoy your favorite herbs and spices. I wouldn’t recommend eating 10 cloves of garlic every night – but you probably wouldn’t want to do that anyway!

The same thing goes with alcohol. We are not saying that you can never have a drink because you’re on a blood thinner – we just recommend drinking in moderation. If you know you’re going to be drinking a little more than normal—around the holidays, for example—then you might not want to schedule your INR* test for the next day because you need to give your body time to level out. However, I do caution patients that if you take warfarin and have more than two drinks a night, you’re increasing your risk of bleeding. So again, I can’t stress enough that moderation is key, and your care team is always happy to connect you with resources if you need help cutting back.

*INR = international normalized ratio, a level that measures how much time it takes for your blood to clot. Most patients need to maintain an INR level between 2 and 3 to be considered in “therapeutic” (or target) range. An INR below the therapeutic range increases the risk of clotting, while an INR above 3 increases the risk of bleeding. INR levels are only monitored in patients who take warfarin and are not useful in patients who take DOACs.

Q: With cold and flu season and, of course, the COVID-19 pandemic, vitamins C and D have been in the news. What can you tell us about using these vitamins when taking anticoagulation?

If you’re taking supplemental doses of vitamin C or D, we wouldn’t ask you to stop that – we would just note it in your patient record and see how you respond. During cold and flu season, many patients take vitamins C and D in hopes of boosting their immune system and improving their overall health. There is no evidence that these vitamins will lessen your risk of getting either the flu or COVID-19, but we do know they’re essential to a healthy immune system, along with rest, hydration, and proper nutrition. It’s important to let us know what immune boosters and vitamins you’re taking, so that we can make sure they don’t interact with your anticoagulation, or with one another.

Q: Finally, laws are changing across the country and people have more access to cannabis and CBD than ever before. Is there any evidence that these products affect anticoagulation?

First, I think that we really need to destigmatize talking about cannabis and CBD, precisely because of the increased access to these products. You shouldn’t be afraid to tell your provider if you’re regularly using marijuana or CBD oils, tablets, or other edible products. In fact, you really need to be telling us because there is evidence that cannabis and CBD can interact with certain medications, including blood thinners.

For starters, cannabis has the potential to:

1. Inhibit platelet production, leading to an increased risk of bleeding
2. Decrease the effects of antiplatelet medications by slowing down the metabolism and increasing the risk for a cardiac event
3. Increase the effects of warfarin, resulting in a higher INR and an increased risk of bleeding
4. Increase the effects of DOACs by slowing down the metabolism of the medication and increasing your risk for bleeding

Remember that as providers, we’re here to help you. Shared decision-making is very important in the anticoagulation world, but for us to make decisions with you, we need to know what you’re using in combination with your anticoagulation. We want to tailor care, make sure that you’re safe, and help you achieve all of your healthcare goals.

*Originally published in The Beat – December 2020. Read the full newsletter here.

1. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146:857–867. [PubMed] [Google Scholar]

2. Le Heuzey JY, Ammentorp B, Darius H, et al. Differences among western European countries in anticoagulation management of atrial fibrillation. Data from the PREFER IN AF registry. Thromb Haemost 2014; 111:833–841. [PubMed] [Google Scholar]

3. Kakkar AK, Mueller I, Bassand JP, et al. Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: perspectives from the international, observational, prospective GARFIELD registry. PLoS One 2013; 8:e63479. [PMC free article] [PubMed] [Google Scholar]

4. Holmes MV, Hunt BJ, Shearer MJ. The role of dietary vitamin K in the management of oral vitamin K antagonists. Blood Rev 2012; 26:1–14. [PubMed] [Google Scholar]

5. Holbrook AM, Pereira JA, Labiris R, et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 2005; 165:1095–1106. [PubMed] [Google Scholar]

6. Hirsh J, Fuster V, Ansell J, et al. American Heart Association/American College of Cardiology F. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. J Am Coll Cardiol 2003; 41:1633–1652. [PubMed] [Google Scholar]

7. Husted S, de Caterina R, Andreotti F, et al. Non-vitamin K antagonist oral anticoagulants (NOACs): no longer new or novel. Thromb Haemost 2014; 111:781–782. [PubMed] [Google Scholar]

8. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361:1139–1151. [PubMed] [Google Scholar]

9. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365:981–992. [PubMed] [Google Scholar]

10. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365:883–891. [PubMed] [Google Scholar]

11. Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369:2093–2104. [PubMed] [Google Scholar]

12. Camm AJ, Kirchhof P, Lip GY, et al. European Heart Rhythm A, European Association for Cardio-Thoracic S. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31:2369–2429. [PubMed] [Google Scholar]

13. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation 2014; 130:e199–267. [PMC free article] [PubMed] [Google Scholar]

14. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 2009; 6:e1000100. [PMC free article] [PubMed] [Google Scholar]

15. American Academy of Neurology. Clinical Practice Guideline Process Manual. Minneapolis, MN, 2011. [Google Scholar]

16. Pedersen FM, Hamberg O, Hess K, et al. The effect of dietary vitamin K on warfarin-induced anticoagulation. J Intern Med 1991; 229:517–520. [PubMed] [Google Scholar]

17. Franco V, Polanczyk CA, Clausell N, et al. Role of dietary vitamin K intake in chronic oral anticoagulation: prospective evidence from observational and randomized protocols. Am J Med 2004; 116:651–656. [PubMed] [Google Scholar]

18. Lubetsky A, Dekel-Stern E, Chetrit A, et al. Vitamin K intake and sensitivity to warfarin in patients consuming regular diets. Thromb Haemost 1999; 81:396–399. [PubMed] [Google Scholar]

19. Cushman M, Booth SL, Possidente CJ, et al. The association of vitamin K status with warfarin sensitivity at the onset of treatment. Br J Haematol 2001; 112:572–577. [PubMed] [Google Scholar]

20. Penning-van Beest FJ, Geleijnse JM, van Meegen E, et al. Lifestyle and diet as risk factors for overanticoagulation. J Clin Epidemiol 2002; 55:411–417. [PubMed] [Google Scholar]

21. Custodio das Dores SM, Booth SL, Martini LA, et al. Relationship between diet and anticoagulant response to warfarin: a factor analysis. Eur J Nutr 2007; 46:147–154. [PubMed] [Google Scholar]

22. Kim KH, Choi WS, Lee JH, et al. Relationship between dietary vitamin K intake and the stability of anticoagulation effect in patients taking long-term warfarin. Thromb Haemost 2010; 104:755–759. [PubMed] [Google Scholar]

23. Rombouts EK, Rosendaal FR, van der Meer FJ. Influence of dietary vitamin K intake on subtherapeutic oral anticoagulant therapy. Br J Haematol 2010; 149:598–605. [PubMed] [Google Scholar]

24. Rasmussen MA, Skov J, Bladbjerg EM, et al. Multivariate analysis of the relation between diet and warfarin dose. Eur J Clin Pharmacol 2012; 68:321–328. [PubMed] [Google Scholar]

25. Zuchinali P, Souza GC, de Assis MC, et al. Dietary vitamin K intake and stability of anticoagulation with coumarins: evidence derived from a clinical trial. Nutr Hosp 2012; 27:1987–1992. [PubMed] [Google Scholar]

26. US Department of Agriculture ARS, Nutrient Data Laboratory. USDA National Nutrient Database for Standard Reference, Release 27 (revised). 2015; Available at: http://www.ars.usda.gov/ba/bhnrc/ndl Accessed date September 3, 2015. [Google Scholar]

27. Schurgers LJ, Shearer MJ, Hamulyak K, et al. Effect of vitamin K intake on the stability of oral anticoagulant treatment: dose-response relationships in healthy subjects. Blood 2004; 104:2682–2689. [PubMed] [Google Scholar]

28. Perez-Andreu V, Roldan V, Gonzalez-Conejero R, et al. Implications of pharmacogenetics for oral anticoagulants metabolism. Curr Drug Metab 2009; 10:632–642. [PubMed] [Google Scholar]

29. Dashti HS, Shea MK, Smith CE, et al. Meta-analysis of genome-wide association studies for circulating phylloquinone concentrations. Am J Clin Nutr 2014; 100:1462–1469. [PMC free article] [PubMed] [Google Scholar]

30. Pignatelli P, Pastori D, Vicario T, et al. Relationship between Mediterranean diet and time in therapeutic range in atrial fibrillation patients taking vitamin K antagonists. Europace 2015; 17:1223–1238. [PubMed] [Google Scholar]